Shield Therapeutics plc

Equities

STX

GB00BYV81293

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 09:07:06 2024-04-23 am EDT			5-day change	1st Jan Change
1.423 ^GBX	-0.14%		-6.69%	-78.76%

Feb. 22	Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024
Feb. 21	FTSE 100 takes hit ahead of FOMC minutes	AN

Shield Therapeutics : Licence agreement secured in Republic of Korea for Accrufer

October 08, 2021 at 07:34 am EDT

Shield Therapeutics plc, announces that it has entered into an exclusive licence agreement for Accrufer with KOREA PHARMA CO.,LTD ('Korea Pharma') in the Republic of Korea ('South Korea' or 'Korea'). Alongside the financial terms of the licence, Korea Pharma will undertake and pay for all activities to achieve marketing authorisation and then commercialise Accrufer in Korea.

Contact:

T: +44 (0)207 186 8500

E: drugsafety@shieldtx.com.

Latest news about Shield Therapeutics plc

Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024	Feb. 22
FTSE 100 takes hit ahead of FOMC minutes	Feb. 21	AN
Shield Therapeutics sinks as strong performance marred by data issues	Feb. 21	AN
Shield Therapeutics plc Announces Unaudited Sales Results for the Year Ended 31 December 2023	Feb. 21	CI
Shield Therapeutics hires former Akili leader as new CFO	Jan. 09	AN
Shield Therapeutics Names New CFO	Jan. 09	MT
Shield Therapeutics Appoints Santosh Shanbhag as New CFO, Effective January 16, 2024	Jan. 08	CI
Comptoir opens restaurant; Intercede wins contract	Dec. 07	AN
FTSE 100 Ends Higher Fueled by Energy Stocks	23-10-12	DJ
Shield Therapeutics Chief Financial Officer Rudolf to leave	23-10-12	AN
AIM WINNERS & LOSERS: Windward sees high contracting activity levels	23-10-12	AN
Shield Therapeutics CFO to Step Down	23-10-12	MT
Shield Therapeutics plc Announces Hans-Peter Rudolf Is Standing Down from His Role as Chief Financial Officer on 20 October 2023	23-10-12	CI
Aston Martin CEO ups stake; Alkemy's lithium deal	23-10-03	AN
Shield Therapeutics completes USD20 million SWK financing	23-10-03	AN
Shield Therapeutics Closes $20 Million Debt Facility with SWK Funding	23-10-03	MT
EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy	23-10-02	AN
Shield Therapeutics Raises $6 Million via Share Issue	23-09-29	MT
FTSE 100 Closes Thursday Slightly Up as Gilt Yields Weigh on Index	23-09-28	DJ
Shield Therapeutics completes GBP5 million share placing	23-09-28	AN
Shield Therapeutics raises funds for US sales push as loss narrows	23-09-28	AN
Earnings Flash (STX.L) SHIELD THERAPEUTICS Posts H1 Revenue $4.3M	23-09-28	MT
Earnings Flash (STX.L) SHIELD THERAPEUTICS Reports H1 Loss $-0.00	23-09-28	MT
Shield Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Shield Therapeutics changes reporting currency to US dollars	23-09-06	AN

Chart Shield Therapeutics plc

Duration

Period

More charts

Company Profile

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shield Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.0142

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SHIELD THERAPEUTICS PLC	-78.76%	13.75M
VERTEX PHARMACEUTICALS INCORPORATED	-0.53%	103B
REGENERON PHARMACEUTICALS, INC.	+3.51%	96.73B
ARGENX SE	+1.48%	21.31B
BIONTECH SE	-15.65%	21.21B
GENMAB A/S	-6.26%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
BEIGENE, LTD.	-21.61%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.75%	13.44B
SAREPTA THERAPEUTICS, INC.	+23.86%	10.98B

Bio Therapeutic Drugs